NVIC

Comirnaty COVID-19 mRNA Vaccine (Age 12 and older)

Published November 10, 2021

In September 2023, the FDA approved an updated mRNA COVID-19 vaccine developed and manufactured by Pfizer-BioNTech for use in persons 12 years and older to target the Omicron variant XBB.1.5. 

Comirnaty COVID-19 mRNA Vaccine was initially authorized for use under EUA as Pfizer-BioNTech COVID-19 vaccine in persons 16 years and older by the in December 2020. This vaccine targeted the original SARS-CoV-2 virus and was authorized to be given as a 2-dose series.  In August 2021 the FDA licensed and granted EUA status to Comirnaty COVID-19 vaccine, an mRNA vaccine developed by BioNTech, for use in persons 16 years of age and older.  The FDA licensed Comirnaty for use in teens 12 through 15 years in July 2022.  In August 2022, the FDA authorized use of a bivalent Pfizer-BioNTech COVID-19 vaccine containing the original SARS-CoV2 strain and the Omicron BA.4/BA.5 variant. 

According to the Comirnaty COVID-19 vaccine package insert “The modRNA in the Pfizer-BioNTech COVID-19 Vaccine is formulated in lipid particles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.”  

Each 0.3mL dose contains 30 mcg of a nucleoside-modified messenger RNA (modRNA) that encodes the viral spike (S) glycoprotein of SARS-CoV-2 Omicron Variant lineage XBB.1.5.

Additional vaccine ingredients include lipids (0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, 0.01 mg potassium chloride, and 6 mg sucrose. The 0.9 percent sodium chloride Injection diluent adds another 2.16 mg sodium chloride per dose. The vaccine does not contain a preservative and the vaccine vial stoppers are free of latex. 

The 2023-2024 Comirnaty COVID-19 vaccine is approved to be given intramuscularly (IM) as a single dose, at least two months after receipt of a previous COVID-19 vaccine dose. 

There is no data available on the co-administration of the Comirnaty COVID-19 Vaccine with any other vaccine product.  

Comirnaty COVID-19 vaccine may not offer protection to all individuals.   This vaccine is also incapable of reducing or stopping transmission of the virus. This means that vaccinated individuals may still be capable of transmitting the virus to others.   

Individuals with immunocompromising conditions, including those who take medications that induce immunosuppression may have a decreased immune response to Comirnaty COVID-19 vaccine.  

According the Comirnaty package insert, data on the safety and effectiveness of the vaccine for use in pregnant women is not known. It is also not known whether the vaccine can be transmitted through breastmilk.  

Comirnaty COVID-19 vaccine has not been studied for its potential to cause cancer, genotoxicity or male infertility. 

On September 12, 2023, the CDC’s ACIP voted to approve use of the 10mcg dose of the 2023-2024 Comirnaty COVID-19 mRNA vaccine targeting the Omicron variant XBB.1.5 in all persons aged 12 years and older. 

Select disease / vaccine